Cellbricks Therapeutics, a Europe-based biotechnology startup focused on 3D bioprinting, has raised €10 million to advance the development of living tissue implants.
The round consists of a €7 million seed investment along with more than €3 million in non-dilutive funding. It was led by Silicon Roundabout Ventures, with participation from SPRIND and ACT Venture Partners.
Cellbricks addresses a critical gap in treating severe soft tissue loss, where conventional solutions such as skin grafts and synthetic implants provide structural repair but fail to restore biological function. The company develops biofabricated, living tissues designed to integrate with the body and enable functional recovery.
The new funding will be used to accelerate preclinical validation of its biofabrication platform, including up to three animal studies, and to advance its lead adipose tissue implant program. These implants are particularly relevant for reconstructive procedures such as breast reconstruction, where achieving natural integration remains a key challenge.
A core advantage of Cellbricks’ technology lies in its ability to vascularize over time, allowing implanted tissues to behave like native tissue. This marks a shift from cosmetic reconstruction toward true regenerative outcomes.
Founded in 2016 and headquartered in Berlin, with operations in Boston, Cellbricks Therapeutics aims to move beyond tissue repair toward enabling functional organ replacement through 3D bioprinting.